In turn, this will permit the expansion of Interleukin Genetics’s distribution network for such genetic tests. Under the agreement, Access Business Group’s existing license to the Interleukin Genetics’s intellectual property will become non-exclusive.
Interleukin Genetics will have the right to brand, market, sell and distribute all genetic tests developed using its existing and future intellectual property, either itself or through additional third party licensees.
Access Business Group will continue to distribute the Heart Health and General Nutrition genetic tests under the Gensona brand name. The agreement will continue to allow Interleukin Genetics to have exclusive ownership of all inventions relating to genetic tests arising from research programs between the companies.
Lewis Bender, CEO at Interleukin Genetics, said: “This is an excellent agreement for Interleukin Genetics as we now have the opportunity to aggressively pursue new partnerships for distribution of the genetic tests and intellectual property created over the years with our partner, Access Business Group.
“We are excited to continue our current efforts to out-license our intellectual property to companies in the biotechnology, molecular diagnostic, pharmaceutical, direct sales and consumer products areas.”